A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N, N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers.
5-MeO-DMT
cognition
dose finding
psychedelic agents
psychoactive
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2021
2021
Historique:
received:
18
08
2021
accepted:
04
11
2021
entrez:
16
12
2021
pubmed:
17
12
2021
medline:
17
12
2021
Statut:
epublish
Résumé
5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) is a tryptamine with ultra-rapid onset and short duration of psychedelic effects. Prospective studies for other tryptamines have suggested beneficial effects on mental health outcomes. In preparation for a study in patients with depression, the present study GH001-HV-101 aimed to assess the impact of four different dose levels of a novel vaporized 5-MeO-DMT formulation (GH001) administered via inhalation as single doses of 2 (
Identifiants
pubmed: 34912222
doi: 10.3389/fphar.2021.760671
pii: 760671
pmc: PMC8667866
doi:
Types de publication
Journal Article
Langues
eng
Pagination
760671Informations de copyright
Copyright © 2021 Reckweg, Mason, van Leeuwen, Toennes, Terwey and Ramaekers.
Déclaration de conflit d'intérêts
This study was funded by GH Research, Dublin, Ireland. JR and JGR are scientific consultants to GH Research. TT is an employee and shareholder of the company GH Research. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Ann N Y Acad Sci. 2008;1129:305-22
pubmed: 18591490
J Trauma Stress. 1998 Jan;11(1):125-36
pubmed: 9479681
Front Pharmacol. 2018 Jan 17;8:974
pubmed: 29387009
Curr Drug Abuse Rev. 2014;7(3):157-64
pubmed: 25563443
Biol Psychiatry. 1996 May 1;39(9):784-95
pubmed: 8731519
Psychopharmacology (Berl). 1987;93(2):158-66
pubmed: 3122248
Front Hum Neurosci. 2016 Jun 14;10:269
pubmed: 27378878
Neuroreport. 1998 Dec 1;9(17):3897-902
pubmed: 9875725
Assessment. 2006 Mar;13(1):27-45
pubmed: 16443717
J Pharm Sci. 2006 Jun;95(6):1308-17
pubmed: 16637053
Psychol Med. 2019 Mar;49(4):655-663
pubmed: 29903051
Pharmacol Biochem Behav. 2000 Jan 1;65(1):75-82
pubmed: 10638639
J Ethnopharmacol. 1994 Jan;41(1-2):1-8
pubmed: 8170151
J Psychopharmacol. 2015 Mar;29(3):289-99
pubmed: 25586396
Psychopharmacology (Berl). 2020 Mar;237(3):773-785
pubmed: 31822925
Front Neurosci. 2018 Aug 06;12:536
pubmed: 30127713
N Engl J Med. 2021 Apr 15;384(15):1402-1411
pubmed: 33852780
J Psychopharmacol. 2016 Dec;30(12):1181-1197
pubmed: 27909165
Curr Drug Metab. 2010 Oct;11(8):659-66
pubmed: 20942780
Psychopharmacology (Berl). 2019 Sep;236(9):2653-2666
pubmed: 30982127
J Psychopharmacol. 2014 Nov;28(11):983-92
pubmed: 25213996
J Psychoactive Drugs. 1999 Apr-Jun;31(2):171-7
pubmed: 10438001
J Psychopharmacol. 2015 Nov;29(11):1182-90
pubmed: 26442957
Front Psychol. 2018 Dec 06;9:2459
pubmed: 30574112
Am J Drug Alcohol Abuse. 2019;45(2):161-169
pubmed: 30822141
J Pers Assess. 1985 Feb;49(1):71-5
pubmed: 16367493
Neuropsychopharmacology. 2009 Jun;34(7):1641-8
pubmed: 19092784
Psychopharmacology (Berl). 2006 Dec;189(3):319-29
pubmed: 17013638
J Psychiatr Res. 2021 May;137:273-282
pubmed: 33730602
J Psychopharmacol. 2018 Jul;32(7):779-792
pubmed: 29708042
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Feb 2;81:1-10
pubmed: 28947181
Clin Pharmacol Ther. 2007 Nov;82(5):572-8
pubmed: 17429350
J Psychopharmacol. 2016 Dec;30(12):1165-1180
pubmed: 27909164
PLoS One. 2010 Feb 02;5(2):e9019
pubmed: 20126400
Neuropsychopharmacology. 2017 Oct;42(11):2105-2113
pubmed: 28443617
Neuropsychopharmacology. 2019 Jun;44(7):1328-1334
pubmed: 30685771
J Psychopharmacol. 2016 Dec;30(12):1279-1295
pubmed: 27856683
Percept Mot Skills. 1973 Aug;37(1):63-70
pubmed: 4728034
Arch Gen Psychiatry. 1994 Feb;51(2):85-97
pubmed: 8297216
Commun Psychopharmacol. 1977;1(2):105-18
pubmed: 414877
Br J Clin Psychol. 2005 Jun;44(Pt 2):227-39
pubmed: 16004657
PLoS One. 2010 Aug 31;5(8):e12412
pubmed: 20824211